Empagliflozin increases kidney weight due to increased cell size in the proximal tubule S3 segment and the collecting duct

The inhibition of renal SGLT2 glucose reabsorption has proven its therapeutic efficacy in chronic kidney disease. SGLT2 inhibitors (SGLTi) have been intensively studied in rodent models to identify the mechanisms of SGLT2i-mediated nephroprotection. So far, the overwhelming effects from clinical tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinha, Frederick, Federlein, Anna, Biesold, Annika, Schwarzfischer, Magdalena, Krieger, Katharina, Schweda, Frank, Tauber, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076569/
https://www.ncbi.nlm.nih.gov/pubmed/37033639
http://dx.doi.org/10.3389/fphar.2023.1118358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076569/
https://www.ncbi.nlm.nih.gov/pubmed/37033639
http://dx.doi.org/10.3389/fphar.2023.1118358

Ejemplares similares